What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Breast cancer
His primary scientific interests are in Breast cancer, Internal medicine, Oncology, Tamoxifen and Surgery.
His study explores the link between Breast cancer and topics such as Gynecology that cross with problems in Relative risk.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology.
He interconnects Estrogen receptor, Trastuzumab and Breast disease in the investigation of issues within Oncology.
His Tamoxifen study incorporates themes from Endometrial cancer, Incidence and Adjuvant therapy.
His Surgery research includes themes of Sentinel lymph node, Clinical trial and Lumpectomy.
His most cited work include:
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (4723 citations)
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer (2000 citations)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (1756 citations)
What are the main themes of his work throughout his whole career to date?
Breast cancer, Internal medicine, Oncology, Tamoxifen and Surgery are his primary areas of study.
His studies deal with areas such as Gynecology and Clinical trial as well as Breast cancer.
His work carried out in the field of Gynecology brings together such families of science as Relative risk and Risk factor.
While the research belongs to areas of Oncology, Joseph P. Costantino spends his time largely on the problem of Cyclophosphamide, intersecting his research to questions surrounding Doxorubicin.
In Tamoxifen, Joseph P. Costantino works on issues like Placebo, which are connected to Triple-negative breast cancer.
His research integrates issues of Endometrial cancer and Estrogen in his study of Breast Cancer Prevention Trial.
He most often published in these fields:
- Breast cancer (67.94%)
- Internal medicine (66.41%)
- Oncology (53.82%)
What were the highlights of his more recent work (between 2012-2020)?
- Internal medicine (66.41%)
- Breast cancer (67.94%)
- Oncology (53.82%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Breast cancer, Oncology, Chemotherapy and Clinical trial.
His Internal medicine research is multidisciplinary, incorporating perspectives in Placebo, Gynecology and Surgery.
Breast cancer is a subfield of Cancer that he studies.
His Cancer study integrates concerns from other disciplines, such as Prospective cohort study and Disease.
The various areas that he examines in his Oncology study include Proportional hazards model, Docetaxel, Bevacizumab, Radiation therapy and Adjuvant therapy.
As a part of the same scientific study, Joseph P. Costantino usually deals with the Clinical trial, concentrating on Pathological and frequently concerns with Surrogate endpoint.
Between 2012 and 2020, his most popular works were:
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (1756 citations)
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data (299 citations)
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial (225 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Breast cancer
Joseph P. Costantino mainly focuses on Breast cancer, Internal medicine, Oncology, Trastuzumab and Lumpectomy.
His biological study focuses on Breast disease.
His research on Internal medicine often connects related areas such as Gynecology.
Joseph P. Costantino has researched Oncology in several fields, including Cancer, Cyclophosphamide, Chemotherapy, Docetaxel and Hazard ratio.
As a member of one scientific family, Joseph P. Costantino mostly works in the field of Trastuzumab, focusing on Adjuvant and, on occasion, Human Epidermal Growth Factor Receptor 2 and Pathology.
He studied Lumpectomy and Radiation therapy that intersect with Epirubicin and Oncotype DX Breast Cancer Assay.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
